These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28559462)

  • 1. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis.
    Marachelian A; Villablanca JG; Liu CW; Liu B; Goodarzian F; Lai HA; Shimada H; Tran HC; Parra JA; Gallego R; Bedrossian N; Young S; Czarnecki S; Kennedy R; Weiss BD; Goldsmith K; Granger M; Matthay KK; Groshen S; Asgharzadeh S; Sposto R; Seeger RC
    Clin Cancer Res; 2017 Sep; 23(18):5374-5383. PubMed ID: 28559462
    [No Abstract]   [Full Text] [Related]  

  • 2. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of Seven Neuroblastoma-Associated mRNAs Detected by Droplet Digital PCR Is Associated with Tumor Relapse/Regrowth of High-Risk Neuroblastoma Patients.
    Thwin KKM; Ishida T; Uemura S; Yamamoto N; Lin KS; Tamura A; Kozaki A; Saito A; Kishimoto K; Mori T; Hasegawa D; Kosaka Y; Nino N; Takafuji S; Iijima K; Nishimura N
    J Mol Diagn; 2020 Feb; 22(2):236-246. PubMed ID: 31837427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
    Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
    Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
    Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
    Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
    Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma.
    Popov A; Druy A; Shorikov E; Verzhbitskaya T; Solodovnikov A; Saveliev L; Tytgat GAM; Tsaur G; Fechina L
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):535-542. PubMed ID: 30603901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
    Corrias MV; Haupt R; Carlini B; Cappelli E; Giardino S; Tripodi G; Tonini GP; Garaventa A; Pistoia V; Pistorio A
    Pediatr Blood Cancer; 2012 Jan; 58(1):43-9. PubMed ID: 21254375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
    Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
    Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [N-myc gene copies in children with neuroblastoma and its clinical significance].
    Ma XL; Gong LP; Zhou CJ; Zhang DW; Jin M; Wang HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1447-51. PubMed ID: 23257451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the MDR1 gene product P-glycoprotein in childhood neuroblastoma.
    Dhooge CR; De Moerloose BM; Benoit YC; Van Roy N; Philippé ; Laureys GG
    Cancer; 1997 Oct; 80(7):1250-7. PubMed ID: 9317175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
    Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
    Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
    Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ppGalNAc-T13: a new molecular marker of bone marrow involvement in neuroblastoma.
    Berois N; Blanc E; Ripoche H; Mergui X; Trajtenberg F; Cantais S; Barrois M; Dessen P; Kågedal B; Bénard J; Osinaga E; Raguénez G
    Clin Chem; 2006 Sep; 52(9):1701-12. PubMed ID: 16873292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.